Vera Therapeutics Q2 2024 Earnings Report $35.88 -0.26 (-0.72%) As of 02/10/2025 04:00 PM Eastern Earnings HistoryForecast Vera Therapeutics EPS ResultsActual EPS-$0.62Consensus EPS -$0.56Beat/MissMissed by -$0.06One Year Ago EPSN/AVera Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AVera Therapeutics Announcement DetailsQuarterQ2 2024Date8/8/2024TimeBefore Market OpensConference Call ResourcesPress ReleaseVERA Earnings HistoryPowered by Vera Therapeutics Earnings HeadlinesVera Therapeutics initiated with an Outperform at Wolfe ResearchFebruary 4, 2025 | markets.businessinsider.comWolfe Research Initiates Coverage of Vera Therapeutics (VERA) with Outperform RecommendationFebruary 4, 2025 | msn.comAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what he might do next. And one widely followed Boston based think tank is stepping forward with their official playbook.February 11, 2025 | Altimetry (Ad)Vera started at buy by Goldman Sachs, atacicept potential citedJanuary 28, 2025 | msn.comVera Therapeutics initiated with a Buy at Goldman SachsJanuary 27, 2025 | markets.businessinsider.comBiotech Market Forecast: Top Trends for Biotech in 2025January 24, 2025 | msn.comSee More Vera Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vera Therapeutics and other key companies, straight to your email. Email Address About Vera TherapeuticsVera Therapeutics (NASDAQ:VERA), a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.View Vera Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?Cirrus Logic Upgraded After Q3 Earnings Beat—More Gains Ahead?Earnings Miss? Amgen’s Dividend Still a Bright SpotPalantir Stock Surges After Blockbuster Earnings: What's Next?Atlassian: Upside Still in Play After Impressive Earnings SpikeWhy Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market Test Upcoming Earnings Cisco Systems (2/12/2025)Trade Desk (2/12/2025)AppLovin (2/12/2025)Equinix (2/12/2025)Sony Group (2/12/2025)Williams Companies (2/12/2025)Airbnb (2/13/2025)Applied Materials (2/13/2025)Barclays (2/13/2025)Relx (2/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
